Of the total borrowings during the month, USD 1.02 billion were raised through automatic route while USD 330 million came via approval route.
AstraZeneca Pharma today said that its board would be meeting on Wednesday to consider a proposal to delist the company.
Fresenius Kabi Oncology has reported a standalone sales turnover of Rs 84.66 crore and a net loss of Rs 63.63 crore for the quarter ended Dec '13
Tech Mahindra | Jubilant Foodworks | Prestige Estates | Wheels India | Tata Chemicals | Future Lifestyle | P&G | Divis Labs | JP Power | JP Infra | Power Grid Corporation | Engineers India | Thomas Cook | Sterling Holidays | NCC and Novartis India are stocks, which are in the news today.
Fresenius Kabi Oncology has reported a standalone sales turnover of Rs 96.15 crore and a net loss of Rs 44.79 crore for the quarter ended Sep '13
Earlier this month the company had said that Securities and Exchange Board of India (SEBI) had advised it to approach Securities Appellate Tribunal (SAT) for seeking any relief, including extension of time.
SAT says that the company is not need to comply with SEBI's conditions. Fresenius kabi had moved to SAT against SEBI's conditional nod for delisting.
Parent company Fresenius Kabi (Singapore) Private Limited holds 81 percent stake in the company as of June 2013. The Royal Bank of Scotland Asia Merchant Bank (Singapore), Macquarie Bank, Morgan Stanley Asia (Singapore) PTE and Nomura Singapore have 6.85 percent stake.
Fresenius Kabi Oncology has reported a sales standalone turnover of Rs 126.87 crore and a net profit of Rs 4.80 crore for the quarter ended Jun '13
The Foreign Investment Promotion Board (FIPB) on Monday cleared six proposals envisaging investments of Rs 855 crore in the pharmaceutical sector, including Fresenius Kabi.
According to Abhishek Agarwal of Fortune Interfinance, one may buy Fresenius Kabi Oncology with a target price of Rs 155 and a stop loss of Rs 140 and sell IDFC.
The US Food and Drug Administration (USFDA) has issued a warning letter to Fresenius Kabi Oncology for violation of manufacturing norms at its Kalyani facility in West Bengal.
According to Prakash Diwan of Altamount Capital Management, one may go long on Fresenius Kabi Oncology and advises to go long on Mahindra & Mahindra Financial Services with a target price of Rs 267 and a stop loss at Rs 250.
According to SP Tulsian of sptulsian.com, one can enter Fresenius Kabi Oncology at current price with a near term target of Rs 140.
Allowing Fresenius Kabi Oncology to initiate the delisting process, Sebi however, said that the company would have to take into account its pre-OFS (Offer for Sale) promoter holding of October 2012 to determine the minimum number of shares to be acquired for the delisting.
Capital market regulator Sebi on Monday allowed Fresenius Kabi Oncology to delist its shares from the Indian stock market and asked the healthcare firm to complete the delisting process within three months -- bringing to an end a long-standing dispute.
Fresenius Kabi Oncology in Friday said it has received a warning letter from the US health regulator asking for more information and implementation of additional corrective and preventive measures regarding GMP non- conformities.
Fresenius Kabi Oncology gained as much as 20 percent intraday on Wednesday after the company said parent company was looking for voluntary delisting of Indian arm. But the stock came off day's high on profit booking.
In CNBC-TV18's popular show Bull's Eye, Nooresh Merani, AMSEC Research shares trading strategy of the day.
Fresenius Kabi Oncology has reported a sales standalone turnover of Rs 205.04 crore and a net profit of Rs 48.36 crore for the quarter ended Dec '12
Shares of multi-national companies (MNCs) will be in focus in the next few weeks as many of them will be required to either reduce promoter shareholding to a regulatory cap of 75 per cent or get delisted.
Fresenius Kabi Oncology has reported a sales turnover of Rs 164.53 crore and a net profit of Rs 26.95 crore for the quarter ended Sep '12
Fresenius Kabi Oncology has reported a sales turnover of Rs 133.49 crore and a net profit of Rs 13.04 crore for the quarter ended Jun '12
UR Associates has come out with its report on pharma sector. The results season has finally come to an end and expectedly pharma sector has outperformed many other sectors.
Fresenius Kabi Oncology has reported a sales turnover of Rs 121.79 crore and a net profit of Rs 4.88 crore for the quarter ended Mar '12